Grace expands CDMO capacity by 25% of South Haven facility in Michigan
Additional capacity broadens Grace’s fine chemical capabilities for API production
Additional capacity broadens Grace’s fine chemical capabilities for API production
NEIAFMR to be developed as the national hub for folk medicine
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Subscribe To Our Newsletter & Stay Updated